MLICM
SYRE icon

Metropolitan Life Insurance Company (MetLife)’s Spyre Therapeutics SYRE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-465
Closed -$92.3K – 2827
2021
Q3 		$92.3K Buy
+465
New +$81.3K ﹤0.01% 2566
2021
Q2 		– Sell
-482
Closed -$95.3K – 2871
2021
Q1 		$95.3K Sell
482
-71
-13% -$13.6K ﹤0.01% 2438
2020
Q4 		$109K Hold
553
– – ﹤0.01% 2316
2020
Q3 		$98K Sell
553
-3
-0.5% -$555 ﹤0.01% 2231
2020
Q2 		$129K Buy
+556
New +$106K ﹤0.01% 2100
2019
Q4 		– Sell
-411
Closed -$78.9K – 2558
2019
Q3 		$78.9K Buy
+411
New +$80.1K ﹤0.01% 2430

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SYRE Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Spyre Therapeutics (SYRE) in Q4 2021, closing a stake of 465 shares — an estimated $92.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SYRE in Q3 2019 and held it in 6 quarters. The position peaked at $129K in Q2 2020. 85 funds tracked by Wall St. Rank hold SYRE as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Spyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 465 Spyre Therapeutics shares in Q4 2021, an estimated $92.3K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Spyre Therapeutics in Q3 2019 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Spyre Therapeutics position peaked at $129K in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.